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Aminopenicillins with or without a β-lactamase inhibitor are widely used in both human and 
veterinary medicine. However, little is known about their differential impact on the gut 
microbiota and development of antimicrobial resistance. 
 
Objectives 




Faeces collected from 42 dogs (21 per treatment group) immediately before, during and 
1 week after termination of oral treatment with amoxicillin or amoxicillin/clavulanic acid 
were analysed by culture and 16S rRNA gene sequence analysis. 
 
Results 
In both groups, bacterial counts on ampicillin selective agar revealed an increase in the 
proportion of ampicillin-resistant Escherichia coli during treatment, and an increased 
occurrence and proportion of ampicillin-resistant enterococci during and after treatment. 16S 
rRNA gene analysis showed reductions in microbial richness and diversity during treatment 
followed by a return to pre-treatment conditions approximately 1 week after cessation of 
amoxicillin or amoxicillin/clavulanic acid treatment. While no significant differences were 
observed between the effects of amoxicillin and amoxicillin/clavulanic acid on microbial 
richness and diversity, treatment with amoxicillin/clavulanic acid reduced the abundance of 
taxa that are considered part of the beneficial microbiota (such as Roseburia, Dialister and 




Our results suggest a limited effect of clavulanic acid on selection of antimicrobial resistance 
and microbial richness when administered orally in combination with amoxicillin. However, 
combination with this β-lactamase inhibitor appears to broaden the spectrum of amoxicillin, 
with potential negative consequences on gut health. 
Introduction 
Aminopenicillins such as amoxicillin alone or in combination with the β-lactamase inhibitor 
clavulanic acid are among the most widely used antimicrobials in both human and veterinary 
medicine. Although amoxicillin and amoxicillin/clavulanic acid are often used 
interchangeably, the addition of clavulanic acid is believed to broaden the antibacterial 
spectrum of amoxicillin.1 It can be hypothesized that such a broader spectrum of 
amoxicillin/clavulanic acid would cause a higher risk of displacing the indigenous microbiota 
and favour development of antimicrobial resistance. Treatment with amoxicillin, 
amoxicillin/clavulanic acid or other β-lactams has been implicated in the selection of resistant 
bacteria of clinical relevance, such as Escherichia coli producing ESBLs in humans and 
various animal species.2–6 Oral treatment with amoxicillin has been shown to change the 
composition and diversity of the human and animal gut microbiota in a drug-specific manner 
as compared with members of other antimicrobial classes.7–16 However, comparative studies 
between closely related antimicrobial drugs are lacking. Such information is important for 
antimicrobial stewardship to make recommendations on how to prioritize drugs that belong to 
the same antimicrobial class and are used for the same indications. 
 
The objective of this study was to investigate changes in the composition of the faecal 
microbiota caused by oral treatment with amoxicillin and amoxicillin/clavulanic acid using 
dogs as a model. The impact of the two drugs on selection of β-lactam-resistant E. coli and 
enterococci was determined by antimicrobial selective culture, and their influence on 
microbial richness and diversity was assessed by 16S rRNA gene sequence analysis. 
 
Materials and methods 
Dog recruitment and sample collection 
Dogs were recruited from two companion animal practices in Denmark. Dogs were enrolled 
in the study if: (i) they were prescribed oral amoxicillin or amoxicillin/clavulanic acid; (ii) 
they had not received local or systemic antimicrobial treatment in the previous month; (iii) 
they did not present with diarrhoea; and (iv) a signed consent form was obtained from their 
owner. Faeces were collected from each dog on day 0 (before treatment), day 5 (during 
treatment) and days 12–14 (1 week after cessation of treatment). Fresh faecal deposits were 
collected by the owners in pre-labelled collection bags and transported to the laboratory by 
courier service. Information about sex, age, weight, health status, indication for antibiotic 
treatment and treatment duration was recorded for each dog. 
 
Sample processing and storage 
A 1 g sample of faeces was suspended in 9 mL of peptone water with 15% glycerol, 
homogenized using a stomacher at maximum speed for 2 min and frozen in triplicate at –
80°C for later culture. Additionally, three samples of 1 g of faeces each were frozen at –80°C 
for microbiome analysis. 
Culture-based analysis 
E. coli and enterococci were used as bacterial indicators of β-lactam resistance due to their 
ubiquitous occurrence in faeces and their role as commensal opportunistic pathogens in both 
humans and animals. Frozen faecal dilutions were thawed to prepare 10-fold dilutions in 
physiological saline up to 10−6. Three 20 μL drops of each dilution were inoculated onto five 
agar media (Oxoid, UK): MacConkey agar; MacConkey supplemented with ampicillin 
(32 mg/L); MacConkey supplemented with cefotaxime (1 mg/L); Slanetz–Bartley agar; and 
Slanetz–Bartley supplemented with ampicillin (16 mg/L). These five media provided counts 
of total E. coli, ampicillin-resistant E. coli, cefotaxime-resistant E. coli, total enterococci and 
ampicillin-resistant enterococci, respectively. MacConkey agar plates were incubated for 24 h 
at 37°C and Slanetz–Bartley agar plates at 42°C for 48 h. Lactose-positive colonies growing 
on MacConkey agar and presumptive enterococcal colonies on Slanetz–Bartley agar were 
quantified, and one representative colony from the highest dilution was identified using 
MALDI-TOF MS (BioMérieux, France). Only colonies growing on MacConkey and Slanetz–
Bartley confirmed by MALDI-TOF MS were considered in the counts of total/resistant E. 
coli and enterococci. If more than one colony morphology was observed, quantification and 
species confirmation were performed separately. 
 
Three types of analysis were performed on the data generated by culture: 
 
(i) The prevalence of dogs carrying each β-lactam resistance indicator was compared between 
sampling times (dependent variable: Day) taking both treatment groups together and each 
treatment group separately; and between treatment groups on each day (dependent variable: 
Treatment). Secondly, the effect of the Treatment duration on the prevalence of positive dogs 
was tested by logistic analysis using the glm function (family=binomial) in R version 3.4.4 
(15 March 2018).17 
 
(ii) Counts of total and resistant bacteria were analysed for each indicator taking into account 
repeated measures by fitting a generalized linear mixed-effects model (GLMM) using the 
glmer function (family=Poisson) of the lme4 package in R.18 Models were built for the counts 
of each bacterial indicator (independent variables: Total E. coli, ampicillin-resistant E. coli, 
cefotaxime-resistant E. coli, Total enterococci and ampicillin-resistant enterococci) adding 
dependent variables Dog and Day as a random effect in the format (1|Dog:Day) to specify the 
clustered nature of the data set; and Treatment and Treatment duration as fixed effects. The 
model that better fitted the data was selected based on the Akaike information criterion 
(AIC). 
 
(iii) The proportions of resistant bacteria calculated as ampicillin-resistant E. coli/Total E. 
coli, cefotaxime-resistant E. coli/Total E. coli and ampicillin-resistant enterococci/Total 
enterococci were compared between days and between treatment groups using Wilcoxon test 
in R. 
 
16S rRNA gene sequence analysis 
Samples were analysed using 16S rRNA gene sequencing at GenoScreen (Lille, France). 
Details on the DNA extraction, sequencing protocols, computation of microbiota diversity 
indices, as well statistical treatment of the results are provided in Supplementary data. 
 
Ethics 
The local ethics and administrative committee at the University Hospital for Companion 
Animals (University of Copenhagen) approved the study protocol prior to commencement. 
According to the Danish Animal Experimentation Act §1.2., no further permission is required 




Sixty-four dogs were enrolled in the study, of which 22 were excluded due to missing 
samples before or during treatment (n = 5), missing sample information (n = 5), 
administration of other antibiotics (n = 5), lack of compliance with antibiotic regimen (n = 3), 
concomitant treatment that may affect the antibiotic pharmacokinetics (n = 1), discontinuation 
of treatment (n = 1), sample arrival to the laboratory after 26 h (n = 1) or wrong sampling time 
(n = 1). The remaining 42 dogs received amoxicillin (n = 21) or amoxicillin/clavulanic acid 
(n = 21) orally at a standard dosage of 10–20 mg/kg twice daily. Five dogs that had been 
treated beyond 7 days were not excluded but collection of the third sample was postponed to 
7 days after cessation of treatment. Characteristics of the two treatment groups are shown in 
Table 1. Based on χ2 tests, the treatment groups had no significant differences in the 
composition of breed, sex, age, weight, treatment duration, day of collection of the second 
and third sample (during and after treatment, respectively), number of days between the 
cessation of treatment and the collection of the third sample or organ system involved in the 
diagnosis (P ≥ 1). Details for each dog are shown in Table S1. In nine dogs (five in the 
amoxicillin group and four in the amoxicillin/clavulanic acid group), the third sample (after 
treatment) was not collected. 
 
Prevalence and counts of β-lactam resistance indicators 
E. coli was isolated from all samples except six (one sample before treatment and two during 
treatment in each group). Based on MALDI-TOF MS, other lactose-positive species isolated 
from MacConkey agar were identified as Klebsiella pneumoniae and Buttiauxella 
agrestis. Enterococcus faecium was the species most frequently isolated from Slanetz–
Bartley agar (54%, 66% and 50% of all enterococci before, during and after treatment, 
respectively), followed by Enterococcus faecalis (40%, 26% and 31% before, during and 
after treatment, respectively). Other Enterococcus species identified at lower frequencies 
included E. avium, E. hirae, E. raffinosus, E. casseliflavus, E. gallinarum and E. durans. E. 
faecium was the major contributor to ampicillin resistance, accounting for 80%, 89% and 
62% of all ampicillin-resistant enterococci before, during and after treatment, respectively. 
Figure 1 shows the prevalence of dogs carrying ampicillin-resistant E. coli, cefotaxime-
resistant E. coli and ampicillin-resistant enterococci on each day and in each treatment group. 
The prevalence of dogs carrying ampicillin-resistant enterococci increased significantly 
during antibiotic treatment taking both treatment groups together (P = 4.35 × 10−5, OR = 5.58, 
95% CI = 2.5–13.62) and separately (amoxicillin: P = 0.0053, OR = 5.8, 95% CI = 1.8–24.9; 
amoxicillin/clavulanic acid: P = 0.0029, OR = 5.4, 95% CI = 1.9–18.64). There were no 
significant differences between treatment groups in the prevalence of dogs carrying any of 
the resistance indicators, and such prevalence was not significantly influenced by treatment 
duration. 
Before treatment, the counts of total E. coli and enterococci ranged from 0 to 2.4 × 109 cfu/g 
(mean = 1.2 × 108, median = 4.7 × 106), and 0 to 5.2 × 107 cfu/g (mean = 6.7 × 106, 
median = 7.3 × 103), respectively. Figure 2 shows counts of total and resistant bacterial indicators 
in both treatment groups. Poisson regression analysis showed significantly higher counts of total 
enterococci in the amoxicillin/clavulanic acid group compared with the amoxicillin group 
(P = 0.0164) (Table 2). This difference between treatment groups was, however, observed on all 
three sampling days, meaning that it was likely to be a random effect not associated with 
treatment. The model that better fitted data on total E. coli counts included the variable Treatment 
duration; however, it did not have a significant effect. For all the remaining indicators, the 
models that better fit the data were those excluding Day, Treatment and Treatment duration, 
indicating a lack of effect of these variables (Table 2). 
The proportion of ampicillin-resistant E. coli and ampicillin-resistant enterococci increased 
significantly during treatment. The increased proportion of resistance returned to initial 
values for ampicillin-resistant E. coli, while it remained significantly higher for ampicillin-
resistant enterococci after the termination of treatment. The proportion of resistant counts was 
not significantly different between treatment groups on any of the days. Figure 3 shows the 
proportions of resistant bacterial counts across days and treatment groups, and the 
resulting P values of the Wilcoxon test comparing the proportions of each resistance indicator 
between days. 
 
Microbial richness and diversity 
Sequencing of the 16S rRNA gene amplicon library generated a total of 4 970 688 reads, with 
an average of 28 243 reads per sample (range 1878–56 947; median 28 168). 
Table S2 provides the abundance matrix (reads) at the genus level. Both antibiotic treatments 
resulted in decreased α-diversity of the faecal microbiota during treatment, as shown by a 
small but significant drop in the Shannon (P = 1.1 × 10−5 for univariate analysis) and Chao1 
(P = 1.3 × 10−3 for univariate analysis) indices (Figure 4). The composition of the bacterial 
community also changed during treatment, as shown by the principal coordinates analysis of 
unweighted (Figure 5) and weighted (not shown) UniFrac distances, corresponding to a 
reduction of the phylum Firmicutes and an increase of Proteobacteria (Table S3 and Figure 
S1). These changes of α- and β-diversity indices were reversed after the termination of 
treatment. Treatment with amoxicillin or amoxicillin/clavulanic acid had a similar impact on 
the α- and β-diversity of the microbiota. 
Effect of amoxicillin (AMX) and amoxicillin/clavulanic acid (AMC) treatments on the α-
diversity of the intestinal microbiota. Mean±SD values of the Shannon index (a) and Chao1 
index (b) in the AMX and AMC groups before, during and after antibiotic treatment. 
ANOVAs on variables Day (Before, During and After) showed a statistical difference for 
sampling times (P = 1 × 10−5 and 1 × 10−3 for the Shannon and Chao1 indices, respectively, 
univariate analysis). The indicated P values correspond to post-hoc Tukey tests performed on 
the variable Day. 
The spectra of activity of the two drugs were analysed comparing the abundance of taxa at 
the family and genus levels between treatment groups on each day and between pairs of days 
within each treatment group. The family- and genus-based analysis showed a similar 
microbiota composition of both treatment groups before the start of treatment, yet different 
dynamics of specific taxa followed. For example, at the genus 
level, Clostridium and Turicibacter decreased in both groups during treatment, while other 
genera (Dialister, Oscillospira, Roseburia and an unclassified genus within Lachnospiraceae) 
decreased only in the amoxicillin/clavulanic acid group. Another remarkable finding was the 
increase of Escherichia in the amoxicillin/clavulanic acid group during treatment and 
decrease in the amoxicillin group after treatment. On average, the proportion 
of Escherichia increased during treatment with either amoxicillin (P = 0.09) or 
amoxicillin/clavulanic acid (P = 9.4 × 10−4) from approximately 4%–5% to approximately 
20%–21% of the total reads per sample. However, whereas this proportion dropped 
drastically (down to 2.5%) after treatment with amoxicillin, it remained high (23%) after 
treatment with amoxicillin/clavulanic acid. 
The dynamics observed at the family level reflected the results of the genus-based analysis in 
Enterobacteriaceae, Turicibacteriaceae and Succinivibrionaceae, whereas other genera 
belonging to Clostridiaceae, Peptostreptococcaceae, Bifidobacteriaceae, Ruminococcaceae, 
Helicobacteraceae and Veillonellaceae did not translate into significant changes at the family 
level. Dynamics of certain families, i.e. Streptococcaceae and Lachnospiraceae, reflected the 
genus results only when referring to the genera Streptococcus, Dorea and Blautia. Differential 
abundance analysis between days and treatment groups is shown in Table 3. 
Discussion 
It is generally accepted that antimicrobial drugs negatively influence the gut microbiome, but 
the impact of some drugs is more deleterious than that of others depending on their spectrum 
of activity. This has been shown by numerous studies assessing the ecological impact of 
antimicrobial drugs belonging to different drug classes.8,10,14–16 This is the first study 
assessing the impact of two closely related formulations (amoxicillin and 
amoxicillin/clavulanic acid), and it provides interesting indications about the effect of 
clavulanic acid on the faecal microbiota. 
Clavulanic acid broadens the spectrum of amoxicillin by including bacterial taxa that can be 
resistant to amoxicillin due to β-lactamase production. These taxa include Bacteroides spp. 
and other bacteria that are normal commensals of the gut and carry chromosomal or plasmid-
mediated β-lactamases.19 Moreover, although clavulanic acid displays limited antibacterial 
activity, there is evidence that it also increases the activity of β-lactams by mechanisms other 
than the inhibition of β-lactamases. Due to these properties of clavulanic acid, 
amoxicillin/clavulanic acid is generally regarded as a drug with a broader spectrum and 
higher selective potential than amoxicillin. Indeed, our study indicates that oral 
administration of clavulanic acid in combination with amoxicillin reduces the abundance of 
the genera Dialister, Oscillospira, Roseburia and one unclassified Lachnospiraceae taxon 
compared with amoxicillin treatment alone. Direct comparison between the amoxicillin and 
amoxicillin/clavulanic acid groups revealed higher amounts 
of Dialister and Roseburia during treatment, and Dialister and Lactococcus after treatment in 
the amoxicillin group (Table 3). These differences suggest that inclusion of clavulanic acid 
affects certain fractions of the commensal gut microbiota that are not affected by amoxicillin 
alone. Some members of Lactococcus, Roseburia, Lachnospiraceae and the less 
known Oscillospira have been reported as short-chain fatty acid (SCFA) producers, 
biomarkers of health or organisms with probiotic potential.20–24 Thus, it appears that some 
organisms that are regarded as beneficial to gut health could be affected by the inclusion of 
clavulanic acid in amoxicillin formulations. The degree of the changes observed at the genus 
level and the importance of a genus within the structure of its particular family reflect the 
dynamics observed in the family-based analysis. Families such as Lachnospiraceae and 
Streptococcaceae are composed of taxa associated with both health and disease, and therefore 
analysis at lower taxonomic levels (genus, or species when possible) may allow a better 
understanding of the health implications of antimicrobial treatment. 
The negative consequences of antimicrobial exposure include selection of opportunistic 
pathogens that reside as commensals in the gut microbiome. The most notable example is E. 
coli, which is one of the most common bacterial pathogens in both humans and dogs. Based 
on culture, total E. coli counts increased slightly during treatment with both drugs (Figure 2). 
This increase of E. coli, together with the observed increase of Proteobacteria in our study is 
in line with previous metagenomics studies reporting an increase of E. coli, 
Enterobacteriaceae and/or Proteobacteria following treatment with amoxicillin or 
amoxicillin/clavulanic acid in humans,13,25 dogs,7 piglets,8,9 Wistar rats10 and farmed 
mink.12 Our sequencing data, however, showed that the genus Escherichia increased 
significantly following treatment with amoxicillin/clavulanic acid only, suggesting a possible 
additional negative effect attributable to clavulanic acid. High counts of intestinal E. coli are 
associated with pathological conditions such as type 2 diabetes, colorectal cancer and 
allergies in humans,26–28 and intestinal bowel disease in humans and dogs.29,30 Moreover, 
dysbiosis characterized by lower bacterial diversity and increased Enterobacteriaceae has 
been associated with increased susceptibility to specific pathogens, improper cognitive or 
immune development and poor response to drugs, including antibiotics, as seen in murine 
infection models and human patients undergoing therapy.28 High concentrations of E. coli in 
faeces may also be a risk factor for urinary tract infections (UTIs), which are normally caused 
by uropathogenic E. coli strains resident in the faecal microbiota of the patient. In that regard, 
previous studies suggest that exposure to antimicrobials is a risk factor for UTI,31 including 
UTI caused by resistant strains.32 The E. coli enrichment observed by 16S rRNA gene 
sequencing following treatment with amoxicillin/clavulanic acid might be explained by the 
limited effects of clavulanic acid on this bacterial species. It has been shown that inhibition of 
amoxicillin/clavulanic acid-susceptible or intermediate E. coli (as defined by in vitro testing 
using a 2:1 ratio of amoxicillin and clavulanic acid) requires drug concentrations that are 
difficult to achieve by oral treatment in the presence of high bacterial concentrations 
(≥107 cfu/mL)33 such as those occurring in faeces. However, this result was not corroborated 
by phenotypic counts of total E. coli, which seemed to be higher in the amoxicillin/clavulanic 
acid-treated group but the increase was not statistically significant (models including 
variables Treatment or Day returned the highest AIC values and showed no significant 
differences between treatments when run; P = 0.332). Phenotypic E. coli counts could be 
inaccurate due to inclusion of lactose-positive colonies belonging to other 
Enterobacteriaceae, as indicated by the detection of Klebsiella or Buttiauxella among the 
single colonies that were selected for MALDI-TOF identification. 
As for the selection of β-lactam resistance, inclusion of clavulanic acid in the treatment did 
not significantly influence the counts of any of the resistance indicators. Oral treatment with 
amoxicillin and amoxicillin/clavulanic acid had similar effects on selection of ampicillin-
resistant E. coli and enterococci, namely an increase in the number of dogs carrying 
ampicillin-resistant enterococci (Table 1) and in the proportion of ampicillin-resistant E. 
coli and ampicillin-resistant enterococci during treatment (Figure 3). While the proportion of 
ampicillin-resistant E. coli returned to the initial values after cessation of therapy, the 
proportion of ampicillin-resistant enterococci remained high. These different dynamics 
suggest a longer term impact of treatment on resistance in enterococci compared with E. coli. 
The low number of samples harbouring cefotaxime-resistant E. coli in the two groups (19 
samples in total) did not allow us to assess the effect of treatment on this important indicator. 
It should be noted that the methodology selected to analyse proportions was different from 
that used to analyse bacterial counts due to the lack of linearity of the data and poor 
behaviour of the models fitting the proportions as a binomial distribution (as number of 
successful/failed cases). 
Both treatments reduced the richness and diversity of the faecal microbiota during treatment 
but α- and β-diversity indices returned to baseline levels after cessation of treatment. This 
finding is corroborated by numerous previous studies on the effect of amoxicillin or 
amoxicillin/clavulanic acid.7,14,25 The short-lived effect found in our study is in accordance 
with the results of a previous study of amoxicillin exposure in healthy dogs, where the 
diversity index returned to pre-exposure levels within 2 weeks.7 However, it is only partly in 
agreement with two previous studies on human volunteers treated with amoxicillin or 
amoxicillin/clavulanic acid (PO 500 mg twice daily for 3/7 days and 875/125 mg twice daily 
for 7 days, respectively).14,25 These studies reported changes in microbial diversity associated 
with the antimicrobial treatment that persisted for longer periods of time (>6 months),14 or 
that recovered only partially 2 weeks after the termination of treatment. This divergence 
between studies could be due to variations in amoxicillin dosage and treatment duration as 
well as methodological or host-related differences. 
In a recent study, pigs were used as a model to evaluate differences between the effects of 
amoxicillin and ertapenem on microbiome composition and selection of antimicrobial 
resistance genes.8 The study evidenced the usefulness of animal models to compare the 
impact of antimicrobial agents on development of dysbiosis and selection of antimicrobial 
resistance. This information is useful for developing recommendations on prudent 
antimicrobial use, since there is an increasing demand for therapeutic guidelines that consider 
the negative consequences of antimicrobial treatment in addition to clinical efficacy. Dogs 
were chosen in this study, as amoxicillin and amoxicillin/clavulanic acid are widely used 
drugs for managing bacterial infections in these companion animals. Moreover, their gut 
microbiome is closer to the human microbiome than the microbiome of either pigs or 
mice,34 suggesting that dogs are better models for studying antimicrobial-mediated dysbiosis 
of the human gut microbiota. 
The time and conditions used to store faecal samples in this study (up to 26 h at room 
temperature) are not expected to have a significant impact on the microbiome based on 
previous studies on the feline faecal microbiota.35 There is evidence that variations observed 
between individuals are larger than the changes introduced by storage conditions such as 
temperature, duration and preservation media.36–39 Moreover, various studies argue that 
temperature or storage duration may not have a radical influence on operational taxonomic 
unit (OTU) composition,37–40 and that the observed changes may not be large enough to mask 
the effect of other conditions under study such as treatment or disease.38 As for other studies 
investigating antimicrobial effects on gut microbiota, the relatively small sample size (21 
dogs/group) is an obvious limitation of the study and it cannot be excluded that additional 
differences between the two treatment groups could have been detected in a larger 
population. 
In conclusion, our study shows that oral treatment with amoxicillin and 
amoxicillin/clavulanic acid similarly affects microbial richness and increases carriage of 
ampicillin-resistant enterococci and ampicillin-resistant E. coli in dog faeces. The impact 
attributable to clavulanic acid appears to be limited to a reduction of some bacterial taxa that 
are known to have beneficial effects on gut health, and may include a possible increase of the 
opportunistic pathogen E. coli. 
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Table 1. Characteristics of the 42 dogs included in the study. Dogs were treated with either 
amoxicillin (AMX) or amoxicillin/clavulanic acid (AMC). 
 AMX-treated group AMC-treated group 
N dogs 21 21 
N dogs with all three samples 16 17 
Female:male 13:8 12:9 
Age (m) Mean= 83m (6y 11m) Mean= 68m (5y 8m) 
Min.= 6m Min.= 4m 
Max.= 180m (15y) Max.= 150m (12y 6m) 
Weight (Kg) Mean= 24.2 Kg Mean= 23.6 Kg 
Min.= 3.5 Kg Min.= 2.1 Kg 
Max.= 46 Kg Max.= 52.5 Kg 
Treatment duration 5 days (n=7) 5 days (n=9) 
7 days (n=12) 7 days (n=9) 
10 days (n=1) 10 days (n=1) 
13 days (n=1) 11 days (n=1) 
14 days (n=1) 
Day of collection of second 
sample (during treatment) 
Day 3 (n=4) Day 3 (n=2) 
Day 4 (n=12) Day 4 (n=13) 
Day 5 (n=5) Day 5 (n=5) 
Day 6 (n=1) 
Day of collection of third 
sample (during treatment) 
Day 10 (n=2) Day 14 (n=2) Day 9 (n=1) Day 13 (n=6) 
Day 11 (n=2) Day 15 (n=1) Day 10 (n=1) Day 14 (n=1) 
Day 12 (n=4) Day 16 (n=1) Day 11 (n=4) Day 17 (n=1) 
Day 13 (n=3) Day 17 (n=1) Day 12 (n=2) Day 18 (n=1) 
Days between cessation of 
third sample  
5 days (n=5) 10 days (n=1) 4 days (n=1) 7 days (n=2) 
6 days (n=6) 12 days (n=1) 5 days (n=2) 8 days (n=1) 




6 days (n=11) 
  System involved in diagnosis dermatology (n=14) dermatology (n=11) 
urogenital (n=5) postoperative (n=3) 
dental (n=1) trauma (n=2) 






Table 2. Summary of the Poisson regression analysis of bacterial counts (cfu) in dogs treated 
with amoxicillin (AMX) or amoxicillin/clavulanic acid (AMC) taking into account repeated 
measures. For each bacterial population, the best model was selected based on AIC analysis. 
The list of variables tested included Day (before/during/after), Treatment (AMX/AMC) and 
Treatment duration (expressed in days). Bold indicates statistical significance (P ≤ 0.05). 
 
Analysed bacterial population 
(independent variable) 
Variables included in 
the model best fitting 
the data (dependent 
variables) Significant outcome  
  random effect  fixed effects  
Total E. 
coli  
(1|Dog:Day)  Treatment duration  
none (Treatment 








(1|Dog:Day)  none  none  
Total 
enterococci  




(1|Dog:Day)  none  none  
 
  
Table 3. Significantly different abundant genera between treatment days (from before to 
during treatment, from during to after treatment and from before to after treatment) within 
each group of dogs treated with amoxicillin (AMX) or amoxicillin/clavulanic acid (AMC), 
and significantly different genera between treatment groups (AMX and AMC) on each 




P value  Adjusted P value  
Differentially abundant genera comparing before and during AMX treatment  
 Clostridium1a  –6.92  6.47 × 10–5  1.65 × 10–3  
 Bifidobacterium  8.12  5.42 × 10–3  4.60 × 10–2  
 Clostridium2a  –1.69  2.37 × 10–3  4.03 × 10–2  
 Clostridium3a  –3.59  5.10 × 10–3  4.60 × 10–2  
 Streptococcusb  –4.92  5.33 × 10–3  4.60 × 10–2  
 Turicibacterb  –12.10  5.34 × 10–16  2.73 × 10–14  
Differentially abundant genera comparing during and after AMX treatment  
 Escherichiab  –3.69  1.19 × 10–4  4.37 × 10–3  
 Lactococcusb  22.00  9.06 × 10–14  4.98 × 10–12  
 Turicibacterb  28.20  4.35 × 10–45  4.78 × 10–43  
Differentially abundant genera comparing before and after AMX treatment  
 Anaerobiospirillumb  –27.8  4.56 × 10–21  4.70 × 10–19  
 Lactococcus  22.6  1.89 × 10–14  9.73 × 10–13  
Differentially abundant genera comparing before and during AMC treatment  
 Clostridium  –7.06  3.20 × 10–5  2.49 × 10–4  
 Dialister  –24.00  2.20 × 10–16  4.62 × 10–15  
 Escherichiab  3.72  1.57 × 10–4  9.44 × 10–4  
 Oscillospira  –6.01  3.55 × 10–5  2.49 × 10–4  
 Roseburia  –7.00  2.14 × 10–6  2.25 × 10–5  
 Turicibacterb  –27.90  8.84 × 10–71  3.71 × 10–69  
 unclassified Clostridiales  –6.32  1.25 × 10–6  1.75 × 10–5  
    unclassified Lachnospiraceae  –2.64  3.64 × 10–03  1.91 × 10–2  
Differentially abundant genera comparing during and after AMC treatment  
 Doreab  3.81  3.00 × 10–4  8.51 × 10–3  
 Sarcina  24.20  2.54 × 10–17  1.08 × 10–15  
 Turicibacterb  25.50  5.71 × 10–42  4.85 × 10–40  
Differentially abundant genera comparing before and after AMC treatment  
 Blautiab  2.26  0.000630  0.0274  
 Helicobacter  –4.77  0.000607  0.0274  
Differentially abundant genera between treatment groups AMX and AMC before treatment  
 None        
Differentially abundant genera between treatment groups AMX and AMC during treatment  
 Dialister  –24.20  1.04 × 10–16  9.76 × 10–15  
 Roseburia  –6.88  5.63 × 10–6  2.65 × 10–4  
Differentially abundant genera between treatment groups AMX and AMC after cessation of 
treatment  
 Dialister  –23.60  6.96 × 10–16  3.69 × 10–14  
 Escherichiab  3.08  1.23 × 10–3  3.27 × 10–2  
 Lactococcus  –23.30  1.69 × 10–15  5.97 × 10–14  
 Sarcina  23.50  6.46 × 10–16  3.69 × 10–14  
a. Clostridium is classified as three families according to the Greengenes v13_8 database: 
Peptostreptococcaceae (Clostridium1), Clostridicaceae (Clostridium2) and 
Lachnospiraceae (Clostridium3). 
b. The significant differences in this genus were also observed at their corresponding family 
level. 
  
Figure 1. Percentage of dogs carrying resistance indicators ampicillin (AMP)-resistant E. 
coli, cefotaxime (CTX)-resistant E. coli and AMP-resistant enterococci before, during and 
1 week after cessation of treatment with amoxicillin (AMX) or amoxicillin/clavulanic acid 
(AMC). AMP-resistant enterococci increased significantly during treatment in both treatment 




Figure 2. Counts of total and resistant bacterial indicators ampicillin (AMP)-resistant E. coli, 
cefotaxime (CTX)-resistant E. coli and AMP-resistant enterococci in faecal samples from 
dogs before, during and after antibiotic treatment with amoxicillin (AMX, n = 21) or 
amoxicillin/clavulanic acid (AMC, n = 21). 
 
  
Figure 3. Proportion of antimicrobial-resistant bacterial indicators (resistant population/total 
population) ampicillin (AMP)-resistant E. coli, cefotaxime (CTX)-resistant E. coli and AMP-
resistant enterococci in faeces from dogs before, during and after antibiotic treatment with 
amoxicillin (AMX) or amoxicillin/clavulanic acid (AMC). Plots include P values resulting 
from comparing the proportions between treatment days (Before, During, After) by Wilcoxon 




Figure 4. Effect of amoxicillin (AMX) and amoxicillin/clavulanic acid (AMC) treatments on 
the α-diversity of the intestinal microbiota. Mean±SD values of the Shannon index (a) and 
Chao1 index (b) in the AMX and AMC groups before, during and after antibiotic treatment. 
ANOVAs on variables Day (Before, During and After) showed a statistical difference for 
sampling times (P = 1 × 10−5 and 1 × 10−3 for the Shannon and Chao1 indices, respectively, 
univariate analysis). The indicated P values correspond to post-hoc Tukey tests performed on 
the variable Day. 
  
  
Figure 5. Principal coordinates analysis (unweighted UniFrac distances) of the faecal 
microbiota composition of dogs before (green), during (blue) and after (red) undergoing 
treatment with amoxicillin (AMX) or amoxicillin/clavulanic acid (AMC). 
 
